These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
259 related items for PubMed ID: 17392531
41. Physical activity/exercise and type 2 diabetes: a consensus statement from the American Diabetes Association. Sigal RJ, Kenny GP, Wasserman DH, Castaneda-Sceppa C, White RD. Diabetes Care; 2006 Jun; 29(6):1433-8. PubMed ID: 16732040 [No Abstract] [Full Text] [Related]
42. Do published ADA studies support the ADA-EASD position statement for the management of hyperglycaemia in type 2 diabetics? Rimareix F, Bauduceau B. Ann Endocrinol (Paris); 2013 Jul; 74(3):207-10. PubMed ID: 23747137 [Abstract] [Full Text] [Related]
43. Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. Goldberg RB, Fonseca VA, Truitt KE, Jones MR. Arch Intern Med; 2008 Jul 28; 168(14):1531-40. PubMed ID: 18663165 [Abstract] [Full Text] [Related]
46. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association: response to Buse et al. Nicolucci A, De Berardis G, Sacco M, Tognoni G. Diabetes Care; 2007 Jun 28; 30(6):e57; author reply e58. PubMed ID: 17526819 [No Abstract] [Full Text] [Related]
47. American College of Endocrinology and American Diabetes Association Consensus statement on inpatient diabetes and glycemic control. ACE/ADA Task Force on Inpatient Diabetes. Diabetes Care; 2006 Aug 28; 29(8):1955-62. PubMed ID: 16873812 [No Abstract] [Full Text] [Related]
50. Type 2 diabetes in pregnancy: exposing deceptive appearances. Langer O. J Matern Fetal Neonatal Med; 2008 Mar 28; 21(3):181-9. PubMed ID: 18297573 [Abstract] [Full Text] [Related]
51. Management of type 2 diabetes: oral agents, insulin, and injectables. Fonseca VA, Kulkarni KD. J Am Diet Assoc; 2008 Apr 28; 108(4 Suppl 1):S29-33. PubMed ID: 18358251 [Abstract] [Full Text] [Related]
52. Hypoglycemic pharmacological treatment of type 2 diabetes: targeting the endothelium. Nathanson D, Nyström T. Mol Cell Endocrinol; 2009 Jan 15; 297(1-2):112-26. PubMed ID: 19038307 [Abstract] [Full Text] [Related]
53. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities. Resmini E, Minuto F, Colao A, Ferone D. Acta Diabetol; 2009 Jun 15; 46(2):85-95. PubMed ID: 19322513 [Abstract] [Full Text] [Related]
57. Dosing of insulin glargine in the treatment of type 2 diabetes. Barnett A. Clin Ther; 2007 Jun 15; 29(6):987-99. PubMed ID: 17692716 [Abstract] [Full Text] [Related]
58. Determining effective insulin analog therapy based on the individualized needs of patients with type 2 diabetes mellitus. Gong WC. Pharmacotherapy; 2008 Oct 15; 28(10):1299-308. PubMed ID: 18823224 [Abstract] [Full Text] [Related]
59. Comment on: Yang et al. (2010) Associations of hyperglycemia and insulin usage with the risk of cancer in type 2 diabetes: the Hong Kong Diabetes Registry. Diabetes;59:1254-1260. Vigneri R, Sava L, Squatrito S, Sciacca L. Diabetes; 2010 Nov 15; 59(11):e24. PubMed ID: 20980466 [No Abstract] [Full Text] [Related]
60. Comment on: Yang et al. (2010) Associations of hyperglycemia and insulin usage with the risk of cancer in type 2 diabetes: the Hong Kong Diabetes Registry. Diabetes;59:1254-1260. Simon D, Balkau B. Diabetes; 2010 Nov 15; 59(11):e25. PubMed ID: 20980467 [No Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]